The U.S. Food and Drug Administration (FDA) has approved Labcorp’s PGDx elio® tissue complete CDx as a companion diagnostic (CDx) for identifying patients with advanced melanoma harboring BRAF V600E or V600K variants who may be eligible for targeted therapy. The approval, announced on August 10, 2026, supports identification of patients who may benefit from FDA-approved BRAF inhibitors or BRAF/MEK inhibitor combinations.

Clinical Takeaway

✔ FDA approval of PGDx elio tissue complete CDx enables clinicians to identify patients with advanced melanoma harboring BRAF V600E/K variants who may benefit from approved targeted therapies, supporting treatment selection.

✔ As a kit-based solution deployable within hospitals and clinical laboratories, the assay broadens access to companion diagnostic testing beyond centralized reference laboratories.

✔ Given the poor prognosis of stage IV melanoma — with a five-year survival rate of only 16% — accurate BRAF variant identification can help guide targeted treatment decisions.

Diagnostic Profile

  • Assay Name: PGDx elio® tissue complete CDx
  • Developer/Manufacturer: Labcorp (NYSE: LH), Burlington, NC
  • Regulatory Status: FDA-approved companion diagnostic (CDx)
  • Approval Date: August 10, 2026
  • Assay Format: Kit-based solution suitable for use in qualified hospitals and clinical laboratories
  • Specimen Type: DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue
  • Technology: Next-generation sequencing (NGS) using high-throughput hybridization-based capture

Target Population & Indicated Use

  • Indication: Patients with melanoma being evaluated for eligibility for FDA-approved BRAF-targeted therapies
  • Biomarkers Detected: BRAF V600E and BRAF V600K variants
  • Therapeutic Context:
    • FDA-approved BRAF inhibitors
    • FDA-approved BRAF/MEK inhibitor combinations
  • Intended Users: Qualified healthcare professionals across hospitals and clinical laboratory settings

Disease Context: Advanced Melanoma

  • Melanoma is the deadliest form of skin cancer
  • Patients diagnosed with stage IV (metastatic) melanoma have a five-year survival rate of only 16%
  • BRAF V600 alterations are clinically actionable genomic findings in melanoma, making accurate variant identification important for treatment planning.
  • Targeted therapies directed at BRAF V600E/K mutations represent a major therapeutic advance, offering meaningful clinical benefit to the subset of patients whose tumors harbor these alterations.

Key Features of PGDx Elio Tissue Complete CDx

  • Companion Diagnostic Function: Identifies patients with melanoma harboring BRAF V600E/K variants who may benefit from FDA-approved BRAF inhibitors or BRAF/MEK inhibitor combinations
  • Kit-Based Deployment: Designed for direct implementation within qualified hospitals and clinical laboratories, supporting broader access to molecular testing while reducing reliance on centralized testing.
  • Sample and Data Retention: The decentralized model allows institutions to retain patient samples and genomic data, which may support future translational and clinical research initiatives
  • Scalability: Designed to support broader population-level access to molecular testing across diverse healthcare settings
  • Genomic Coverage: The NGS-based assay can detect single-nucleotide variants, small insertions and deletions, copy-number amplifications, and translocations.

Key Clinical Implications

✔ Oncologists and dermatology-oncology teams should be aware that PGDx elio tissue complete CDx is now FDA-approved for companion diagnostic use in melanoma, providing an additional FDA-approved option for BRAF V600E/K variant identification when targeted therapy is being considered.

✔ The kit-based format may reduce barriers to testing access by allowing qualified hospitals and clinical laboratories to implement the assay locally rather than relying exclusively on centralized reference laboratories.

✔ Institutional adoption of in-house companion diagnostic platforms like this one may also support local biobanking and genomic data infrastructure, with downstream benefits for research and clinical trial enrollment.

✔ BRAF mutation testing remains an important component of treatment selection in advanced melanoma; this FDA approval provides an additional validated testing option for healthcare systems seeking to expand or internalize their molecular diagnostic capabilities.

Bottom Line

The FDA approval of Labcorp’s PGDx elio® tissue complete CDx adds a new companion diagnostic option for identifying BRAF V600E/K variants in melanoma. As a kit-based NGS assay that can be implemented within qualified hospital and clinical laboratory settings, PGDx elio tissue complete CDx may broaden access to molecular testing while allowing institutions to retain patient samples and genomic data. Given the established role of BRAF-directed therapy in appropriately selected patients with BRAF V600–mutated melanoma, accurate molecular testing remains an important component of treatment selection.

Sources: